- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Inhaled Corticosteroids associated with increased risk of fracture in patients with COPD
Chronic obstructive pulmonary disease (COPD) is a third leading cause of death in world. It is a heterogeneous airway disease, characterized by persistent respiratory symptoms and gradual airflow limitation. Patients with COPD have an increased risk of osteoporosis and fractures, but screening and prophylactic measures to prevent both disorders are often neglected in this population.
Inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs) and long-acting muscarinic receptor antagonists (LAMAs) are three independent inhaled drugs, which can be used alone or in combination in the process of the disease progression to reduce the burden of COPD. The fracture risk of patients with COPD treated with ICSs is controversial and large-scale randomized controlled trials also couldn’t give a proper insight into the problem. The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) suggests ICS use has been restricted only to selected COPD patients mainly based on the risk of exacerbations, high blood eosinophilia, or asthmatic.
The recent systematic review and meta-analysis including 44 RCTs was conducted to reveal the effect of inhaled corticosteroids on the fracture risk of COPD patients. The findings of the review are published in BMC Pulmonary Medicine. The review found that inhalation therapy with ICSs, especially ICS/LABA or triple therapy, was associated with increased the risk of fracture in patients with COPD compared with inhaled therapy without ICS. Moreover, different inhalation devices of the same drug also had differences in risk of fracture.
The two reviewers independently retrieved randomized controlled trials of inhaled corticosteroids or combinations of inhaled corticosteroids in the treatment of COPD from PubMed, Embase, Medline, Cochrane Library, and Web of Science. The primary outcome was a fracture event. This study was registered at PROSPERO (CRD42022366778).
The key findings of the study are
• Out of Forty-four RCTs were performed in 87,594 patients. Inhaled therapy containing ICSs (RR, 1.19; 95%CI, 1.04–1.37; P = 0.010), especially ICS/LABA (RR, 1.30; 95%CI, 1.10–1.53; P = 0.002) and triple therapy (RR, 1.49; 95%CI, 1.03–2.17; P = 0.04) were significantly associated with the increased risk of fracture in COPD patients when compared with inhaled therapy without ICSs.
• Subgroup analyses showed that treatment duration ≥ 12 months (RR, 1.19; 95%CI, 1.04–1.38; P = 0.01), budesonide therapy (RR, 1.64; 95%CI., 1.07–2.51; P = 0.02), fluticasone furoate therapy (RR, 1.37; 95%CI, 1.05–1.78; P = 0.02).
• The mean age of study participants ≥ 65, and GOLD stage III(RR, 1.18; 95%CI, 1.00–1.38; P = 0.04) were significantly associated with an increased risk of fracture.
• In addition, budesonide ≥ 320 ug bid via MDI (RR, 1.75; 95%CI, 1.07–2.87; P = 0.03) was significantly associated with the increased risk of fracture.
Researchers concluded that “Inhalation therapy with ICSs, especially ICS/LABA or triple therapy, increased the risk of fracture in patients with COPD compared with inhaled therapy without ICS. Treatment duration, mean age of participants, GOLD stage, drug dosage form, and drug dose participated in this association. Moreover, different inhalation devices of the same drug also had differences in risk of fracture.”
Reference: Peng, S., Tan, C., Du, L. et al. Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med 23, 304 (2023). https://doi.org/10.1186/s12890-023-02602-5
MSc. Neuroscience
Niveditha Subramani a MSc. Neuroscience (Faculty of Medicine) graduate from University of Madras, Chennai. Ambitious in Neuro research having worked in motor diseases and neuron apoptosis is interested in more of new upcoming research and their advancement in field of medicine. She has an engrossed skill towards writing and her roles at Medical dialogue include Sr. Content writer. Her news covers new discoveries and updates in field of medicine. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751